References
- Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med Volume 1999; 341:1565-1571.
- Yakoub-Agha I, Attal M, Dumontet C, et al. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients. Report of the Intergroupe Francophone du Myélome (IFM). Hematol J 2002; 3: 185-92.
- Osman K, Comenzo R, Rajkumar S. V Deep Venous Thrombosis and Thalidomide Therapy for Multiple Myeloma N Engl J Med 2001; 344:1951-1952 .
- Raijkumar SV, Gertz MA, Witzig TE. Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. N Engl J Med 2000; 343:972-73.
- Morgan AE, Smith WK, Levenson JL. Reversible dementia due to thalidomide therapy for multiple myeloma. N Engl J Med 2003; 348:1821-1822.
- Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21:16-9
- Bernardeschi P, Dentico P, Rossi S, Fiorentini G, Turano E. Low-dose thalidomide plus monthly high-dose oral dexamethasone (Thali-Dexa): results, prognostic factors and side effects in eigth patients previously treated with multiple myeloma. J Exp Clin Cancer Res 2003; 22:129-33 Supplement.
- Cavenagh JD, for the British Committee for standards in Haematology/Oncology Task Force. Guidelines. Thalidomide in multiple myeloma: current status and future prospects. Br J Haematol 2003; 120:18-26.
- Kropff MH, Inning G, Mitterer M, et al. Hyperfractinated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (Hyper-CDT) in primary refractory or relapsed multiple myeloma. Blood 2000; 96:168a.
- Cavo M, Zamagni E, Tosi P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004;89:826-831.